B A Teicher

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    Anticancer Res 18:2567-73. 1998
  2. ncbi PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    In Vivo 11:301-11. 1997
  3. ncbi Acute in vivo resistance in high-dose therapy
    B A Teicher
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 4:483-91. 1998
  4. ncbi The proteasome inhibitor PS-341 in cancer therapy
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, Massachusetts 02115, USA
    Clin Cancer Res 5:2638-45. 1999
  5. ncbi Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo
    A Asea
    Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Int J Hyperthermia 17:347-56. 2001
  6. ncbi Prostate carcinoma response to cytotoxic therapy: in vivo resistance
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA, USA
    In Vivo 11:453-61. 1997
  7. ncbi Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 42:24-30. 1998
  8. ncbi beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA 02115
    Cancer Chemother Pharmacol 33:229-38. 1993
  9. ncbi A carbonic anhydrase inhibitor as a potential modulator of cancer therapies
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA 02115
    Anticancer Res 13:1549-56. 1993
  10. ncbi Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation
    S A Holden
    Dana Farber Cancer Institute, Boston, MA 02115
    Radiother Oncol 18:59-70. 1990

Collaborators

Detail Information

Publications16

  1. ncbi Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    Anticancer Res 18:2567-73. 1998
    ....
  2. ncbi PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    In Vivo 11:301-11. 1997
    ....
  3. ncbi Acute in vivo resistance in high-dose therapy
    B A Teicher
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 4:483-91. 1998
    ..High-dose combination regimens required dose reduction of the drugs, which resulted in decreased tumor growth delays...
  4. ncbi The proteasome inhibitor PS-341 in cancer therapy
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, Massachusetts 02115, USA
    Clin Cancer Res 5:2638-45. 1999
    ..c. tumor and was highly effective against disease metastatic to the lungs. The proteasome is an interesting new target for cancer therapy, and the proteasome inhibitor PS-341 warrants continued investigation in cancer therapy...
  5. ncbi Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo
    A Asea
    Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Int J Hyperthermia 17:347-56. 2001
    ..These experiments, thus, suggest the use of Quercetin as a hyperthermia sensitizer in the treatment of prostate carcinoma...
  6. ncbi Prostate carcinoma response to cytotoxic therapy: in vivo resistance
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA, USA
    In Vivo 11:453-61. 1997
    ..These results support the hypothesis that the drug resistance of prostate carcinoma is manifest in vivo, and that in vivo high levels of TGF-beta may protect these tumors from cytotoxic cancer therapies...
  7. ncbi Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo
    B A Teicher
    Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 42:24-30. 1998
    ....
  8. ncbi beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA 02115
    Cancer Chemother Pharmacol 33:229-38. 1993
    ..These results indicate that agents that inhibit the breakdown of the extracellular matrix can be useful additions to the treatment of solid tumors...
  9. ncbi A carbonic anhydrase inhibitor as a potential modulator of cancer therapies
    B A Teicher
    Dana Farber Cancer Institute, Boston, MA 02115
    Anticancer Res 13:1549-56. 1993
    ..The mechanism may involve its ability to acidify the intratumoral environment, but other mechanisms can not be excluded...
  10. ncbi Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation
    S A Holden
    Dana Farber Cancer Institute, Boston, MA 02115
    Radiother Oncol 18:59-70. 1990
    ..6-fold sparing of the dim cell population. Our results indicate that treatment strategies directed against both oxic and hypoxic tumor subpopulations can markedly increase the tumor cell kill achieved by radiation...
  11. ncbi Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype
    G Chen
    Dana Farber Cancer Institute, Division of Cancer Pharmacology, Harvard Medical School, Boston, MA 02115, USA
    Cancer Biochem Biophys 16:139-55. 1998
    ....
  12. ncbi Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial
    R S Herbst
    Division of Adult Oncology, Lowe Cancer Center for Thoracic Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA
    Cancer Chemother Pharmacol 48:151-9. 2001
    ..However, hematologic toxicities, as found in this study, could probably be reduced with treatment on days 1 and 8 every 21 days, and current literature would suggest this to be the preferred schedule...
  13. ncbi Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker
    M Nozue
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Surg Oncol 66:30-8. 1997
    ..These results were also compared to the immunohistochemical staining of 2-nitromidazole adducts...
  14. ncbi Effect of hypoxia and acidosis on the cytotoxicity of mitoxantrone, bisantrene and amsacrine and their platinum complexes at normal and hyperthermic temperatures
    T S Herman
    Dana Farber Cancer Institute, Boston, MA 02115
    Anticancer Res 12:827-36. 1992
    ..45 versus pH 7.40, although this finding did not correlate with cytotoxicity. These results suggest that PtCl4(MITOX)2 and PtCl4(m-AMSA)2 may be highly interactive drugs with local hyperthermia...
  15. ncbi Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro
    K W Rosbe
    Dana Farber Cancer Institute, Boston, MA 02115
    Cancer Chemother Pharmacol 25:32-6. 1989
    ..Therefore, when lonidamine was present during exposure to the alkylating agent and its presence was then extended for an additional 12 h, a synergistic cell kill was produced with all four alkylating agents tested...
  16. ncbi Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation
    A Asea
    Department of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Int J Hyperthermia 17:401-14. 2001
    ..01) inhibition of hyperthemia-induced serum prostaglandin E2. These findings indicate that NSAID may have both sensitizing effects on prostate tumour growth and may function by inhibiting prostaglandin synthesis...